Fighting Cancer with
a Single Draw of Blood
Dedicated to advancing precision cancer
care for the benefit of patients everywhere.
The Promise of Liquid Biopsy
Lucence makes ultrasensitive and non-invasive liquid biopsy tests for cancer detection and treatment selection. Lucence’s flagship test, LiquidHALLMARK® is swift, simple, and sensitive. Powered by AmpliMARK™, the Company’s proprietary amplicon-based sequencing technology, LiquidHALLMARK® covers a wide range of clinically relevant biomarkers, including mutations in 80 genes, fusions in 10 genes, and somatic variants in 15 cancer types.
LiquidHALLMARK® can provide deep insights into a patient’s cancer, including cancer-driving gene mutations and viruses, from a single blood draw for less invasive precision cancer care.
AmpliMARK™: A Paradigm Shift in Precision Oncology
Lucence’s amplicon-based sequencing technology AmpliMARK™ uses a unique molecular barcode and error correction technology that improves test sensitivity across multiple mutation types for single nucleotide variants and fusion genes. AmpliMARK™ is the foundational breakthrough technology in Lucence’s liquid biopsy tests.
